Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Vector1 who wrote (4913)	7/21/1998 3:21:00 PM
From: Peter Singleton	Read Replies (1) of 6136

fyi, on the status of the GARFT program (AG2034 et al). AG2034 is wrapping up PI with 2034. AGPH has a follow-on molecule, 2037, that they will look at further to decide which one (if either) to take forward in large scale trials. don't know any more details than that. Net is, program will take longer to provide visibility on whether or not a marketable drug might emerge. Just wanted to post (and clarify this) since it was mentioned on Yahoo earlier. Peter also, like all the rest of you guys, looking forward to the earnings release and to reading the tea leaves going forward

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next